{"protocolSection": {"identificationModule": {"nctId": "NCT01318135", "orgStudyIdInfo": {"id": "SYR-322/OCT-005"}, "secondaryIdInfos": [{"id": "JapicCTI-090902", "type": "REGISTRY", "domain": "JapicCTI"}, {"id": "U1111-1119-6196", "type": "REGISTRY", "domain": "WHO"}], "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan", "officialTitle": "A Long-term, Open-label Extension Study to Investigate the Long-term Safety of Alogliptin When Used in Combination With Sulfonylurea or Metformin in Subjects With Type 2 Diabetes in Japan"}, "statusModule": {"statusVerifiedDate": "2012-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-01"}, "primaryCompletionDateStruct": {"date": "2010-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-03-16", "studyFirstSubmitQcDate": "2011-03-16", "studyFirstPostDateStruct": {"date": "2011-03-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-06-08", "resultsFirstSubmitQcDate": "2012-07-07", "resultsFirstPostDateStruct": {"date": "2012-08-16", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-07-07", "lastUpdatePostDateStruct": {"date": "2012-08-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To evaluate the efficacy and safety of alogliptin administered as an add-on to sulfonylurea (glimepiride) or metformin, once daily (QD), twice daily (BID) or three times daily (TID).", "detailedDescription": "Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.\n\nTakeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.\n\nThis was a phase 2/3, multicenter, open-label study, in participants who had completed the core phase 2/3 sulfonylurea add-on study (SYR-322/CCT-005; NCT01318083) or the core phase 2/3 metformin add-on study (SYR-322/CCT-006; NCT01318109) to evaluate the safety and efficacy of alogliptin administered as an add-on to a sulfonylurea (glimepiride) or metformin continuously for 40 weeks (52 weeks from the start of study treatment with alogliptin in the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study)."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Diabetes Mellitus - Type 2", "Diabetes Mellitus", "Drug Therapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 576, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Alogliptin and glimepiride"]}, {"label": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Alogliptin and glimepiride"]}, {"label": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Alogliptin and metformin"]}, {"label": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Alogliptin and metformin"]}], "interventions": [{"type": "DRUG", "name": "Alogliptin and glimepiride", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.", "armGroupLabels": ["Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID"], "otherNames": ["SYR-322", "Amaryl"]}, {"type": "DRUG", "name": "Alogliptin and glimepiride", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.", "armGroupLabels": ["Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID"], "otherNames": ["SYR-322", "Amaryl"]}, {"type": "DRUG", "name": "Alogliptin and metformin", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.", "armGroupLabels": ["Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID"], "otherNames": ["SYR-322", "Glycoran"]}, {"type": "DRUG", "name": "Alogliptin and metformin", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.", "armGroupLabels": ["Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID"], "otherNames": ["SYR-322", "Glycoran"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Adverse Events.", "description": "Treatment-emergent adverse events (TEAE) are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.", "timeFrame": "52 Weeks."}], "secondaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 8).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 8."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 12).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 12."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 16).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 16."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 20).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 20."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 24).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 24."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 28).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 28."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 32).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 32."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 36).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 36."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 40).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 40."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 44).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 44."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 48).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 48."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 52).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 52."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Final Visit).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Final Visit (up to 52)."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 8).", "description": "The change between the value of fasting blood glucose collected at week 8 and baseline.", "timeFrame": "Baseline and Week 8."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 12).", "description": "The change between the value of fasting blood glucose collected at week 12 and baseline.", "timeFrame": "Baseline and Week 12."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 16).", "description": "The change between the value of fasting blood glucose collected at week 6 and baseline.", "timeFrame": "Baseline and Week 16."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 20).", "description": "The change between the value of fasting blood glucose collected at week 20 and baseline.", "timeFrame": "Baseline and Week 20."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 24).", "description": "The change between the value of fasting blood glucose collected at week 24 and baseline.", "timeFrame": "Baseline and Week 24."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 28).", "description": "The change between the value of fasting blood glucose collected at week 28 and baseline.", "timeFrame": "Baseline and Week 28."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 32).", "description": "The change between the value of fasting blood glucose collected at week 32 and baseline.", "timeFrame": "Baseline and Week 32."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 36).", "description": "The change between the value of fasting blood glucose collected at week 36 and baseline.", "timeFrame": "Baseline and Week 36."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 40).", "description": "The change between the value of fasting blood glucose collected at week 40 and baseline.", "timeFrame": "Baseline and Week 40."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 44).", "description": "The change between the value of fasting blood glucose collected at week 44 and baseline.", "timeFrame": "Baseline and Week 44."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 48).", "description": "The change between the value of fasting blood glucose collected at week 48 and baseline.", "timeFrame": "Baseline and Week 48."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Week 52).", "description": "The change between the value of fasting blood glucose collected at week 52 and baseline.", "timeFrame": "Baseline and Week 52."}, {"measure": "Change From Baseline in Fasting Blood Glucose (Final Visit).", "description": "The change between the value of fasting blood glucose collected at final visit and baseline.", "timeFrame": "Baseline and Final Visit (up to Week 52)."}, {"measure": "Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).", "description": "The change between the value of blood glucose measured by the meal tolerance test collected at week 12 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.", "timeFrame": "Baseline and Week 12."}, {"measure": "Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 24).", "description": "The change between the value of blood glucose measured by the meal tolerance test collected at week 24 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.", "timeFrame": "Baseline and Week 24."}, {"measure": "Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 52).", "description": "The change between the value of blood glucose measured by the meal tolerance test collected at week 52 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.", "timeFrame": "Baseline and Week 52."}, {"measure": "Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).", "description": "The change between the value of blood glucose measured by the meal tolerance test collected at final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.", "timeFrame": "Baseline and Final Visit (up to Week 52)."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nCommon criteria that applied to participants completing both the core phase 2/3 sulfonylurea add-on study and those completing the core phase 2/3 metformin add-on study:\n\n1. Had completed the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study.\n2. Was capable of understanding and complying with protocol requirements.\n3. Signed a written informed consent form prior to the initiation of any study procedure.\n\nExclusion Criteria:\n\nCommon criteria that applied to participants completing both the core phase 2/3 sulfonylurea add-on study and those completing the core phase 2/3 metformin add-on study:\n\n1. With clinical manifestation of hepatic impairment (eg, an aspartate aminotransferase or alanine aminotransferase value of 2.5 times or more of the upper reference limit at Week 8 of the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study).\n2. With clinical manifestation of renal impairment (eg, a creatinine value of 1.5 times or more of the upper reference limit at Week 8 of the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study).\n3. With serious cardiac disease, cerebrovascular disorder, or serious pancreatic or hematological disease (eg, a subject who requires hospital admission).\n\nCriteria that applied only to participants completing the core phase 2/3 metformin add-on study:\n\n1. With history or symptoms of lactic acidosis.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "64 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Professor, Diabetes and Endocrine Division", "affiliation": "Department of Medicine, Kawasaki Medical School", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "24843617", "type": "DERIVED", "citation": "Seino Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. J Diabetes Investig. 2012 Dec 20;3(6):517-25. doi: 10.1111/j.2040-1124.2012.00226.x. Epub 2012 Jul 12."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants who had completed a core phase 2/3 glimepiride (SYR-322/CCT-005; NCT01318083) or metformin (SYR-322/CCT-006; NCT01318109) add-on study were enrolled in one of four, once daily (QD) or twice-daily (BID) treatment groups. Five participants completed OCT-005 study without receiving the study drug.", "recruitmentDetails": "Participants enrolled at 58 investigative sites in Japan from 06 January 2009 to 23 January 2010.", "groups": [{"id": "FG000", "title": "CCT/005 - 12.5 mg Dose Group* \u2192 12.5 mg Combination Group", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.\n\n\\*for participants from the 12.5 mg combination dosing ARM of the SYR-322/CCT-005 (NCT01318083) core phase 2/3 glimepiride add-on study."}, {"id": "FG001", "title": "CCT/005 - 25 mg Dose Group* \u2192 25 mg Combination Dose Group", "description": "Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.\n\n\\*for participants from the 25 mg combination dosing ARM of the SYR-322/CCT-005 (NCT01318083) core phase 2/3 glimepiride add-on study."}, {"id": "FG002", "title": "Glimepiride Monotherapy Group* \u2192 12.5 mg Combination Group", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.\n\n\\*for participants from the glimepiride 1, 2, 3 or 4 mg dosing ARM of the SYR-322/CCT-005 (NCT01318083) core phase 2/3 glimepiride add-on study."}, {"id": "FG003", "title": "Glimepiride Monotherapy Group* \u2192 25 mg Combination Group", "description": "Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.\n\n\\*for participants from the glimepiride 1, 2, 3 or 4 mg dosing ARM of the SYR-322/CCT-005 (NCT01318083) core phase 2/3 glimepiride add-on study."}, {"id": "FG004", "title": "CCT/006 - 12.5 mg Dose Group* \u2192 12.5 mg Combination Group", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.\n\n\\*for participants from the 12.5 mg combination dosing ARM of the SYR-322/CCT-006 (NCT01318109) core phase 2/3 metformin add-on study."}, {"id": "FG005", "title": "CCT/006 - 25 mg Dose Group* \u2192 25 mg Combination Group", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.\n\n\\*for participants from the 25 mg combination dosing ARM of the SYR-322/CCT-006 (NCT01318109) core phase 2/3 metformin add-on study."}, {"id": "FG006", "title": "Metformin Monotherapy Group* \u2192 12.5 mg Combination Group", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.\n\n\\*for participants from the metformin 500 mg or 750 mg dosing ARM of the SYR-322/CCT-006 (NCT01318109) core phase 2/3 metformin add-on study."}, {"id": "FG007", "title": "Metformin Monotherapy Group* \u2192 25 mg Combination Group", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.\n\n\\*for participants from the metformin 500 mg or 750 mg dosing ARM of the SYR-322/CCT-006 (NCT01318109) core phase 2/3 metformin add-on study."}], "periods": [{"title": "Enrolled - Long-Term Extension Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "99"}, {"groupId": "FG001", "numSubjects": "102"}, {"groupId": "FG002", "numSubjects": "46"}, {"groupId": "FG003", "numSubjects": "49"}, {"groupId": "FG004", "numSubjects": "91"}, {"groupId": "FG005", "numSubjects": "90"}, {"groupId": "FG006", "numSubjects": "50"}, {"groupId": "FG007", "numSubjects": "49"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "97"}, {"groupId": "FG001", "numSubjects": "102"}, {"groupId": "FG002", "numSubjects": "46"}, {"groupId": "FG003", "numSubjects": "49"}, {"groupId": "FG004", "numSubjects": "91"}, {"groupId": "FG005", "numSubjects": "90"}, {"groupId": "FG006", "numSubjects": "50"}, {"groupId": "FG007", "numSubjects": "49"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Treatment Complications", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}]}, {"title": "Entered - Long-Term Extension Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Patients participated in CCT-005 but not entered OCT-005 are excluded in Participant Flow.", "numSubjects": "97"}, {"groupId": "FG001", "comment": "Patients participated in CCT-005 but not entered OCT-005 are excluded in Participant Flow.", "numSubjects": "102"}, {"groupId": "FG002", "comment": "Patients participated in CCT-005 but not entered OCT-005 are excluded in Participant Flow.", "numSubjects": "46"}, {"groupId": "FG003", "comment": "Patients participated in CCT-005 but not entered OCT-005 are excluded in Participant Flow.", "numSubjects": "49"}, {"groupId": "FG004", "comment": "Patients participated in CCT-006 but not entered OCT-005 are excluded in Participant Flow.", "numSubjects": "90"}, {"groupId": "FG005", "comment": "Patients participated in CCT-006 but not entered OCT-005 are excluded in Participant Flow.", "numSubjects": "87"}, {"groupId": "FG006", "comment": "Patients participated in CCT-006 but not entered OCT-005 are excluded in Participant Flow.", "numSubjects": "50"}, {"groupId": "FG007", "comment": "Patients participated in CCT-006 but not entered OCT-005 are excluded in Participant Flow.", "numSubjects": "49"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "296 participants enrolled and 294 completed glimepiride add-on study and entered the present study.", "numSubjects": "80"}, {"groupId": "FG001", "comment": "296 participants enrolled and 294 completed glimepiride add-on study and entered the present study.", "numSubjects": "89"}, {"groupId": "FG002", "comment": "296 participants enrolled and 294 completed glimepiride add-on study and entered the present study.", "numSubjects": "38"}, {"groupId": "FG003", "comment": "296 participants enrolled and 294 completed glimepiride add-on study and entered the present study.", "numSubjects": "42"}, {"groupId": "FG004", "comment": "280 participants enrolled and 276 completed metformin add-on study and entered the present study.", "numSubjects": "81"}, {"groupId": "FG005", "comment": "280 participants enrolled and 276 completed metformin add-on study and entered the present study.", "numSubjects": "83"}, {"groupId": "FG006", "comment": "280 participants enrolled and 276 completed metformin add-on study and entered the present study.", "numSubjects": "49"}, {"groupId": "FG007", "comment": "280 participants enrolled and 276 completed metformin add-on study and entered the present study.", "numSubjects": "46"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "1"}]}, {"type": "Use of Excluded Medications", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "BG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "BG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "BG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "150"}, {"groupId": "BG001", "value": "152"}, {"groupId": "BG002", "value": "142"}, {"groupId": "BG003", "value": "145"}, {"groupId": "BG004", "value": "589"}]}], "measures": [{"title": "Age, Customized", "description": "Participants randomized in core phase 2/3 glimepiride add-on study, excluding those randomized to the \"glimepiride monotherapy group\" was 304. Participants randomized in core phase 2/3 metformin add-on study, excluding those randomized to the \"metformin monotherapy group\" was 287. The following are included in baseline: Column 1: 7 patients participated in CCT-005 but not entered OCT-005; Column 2: 1 participated in CCT-005 but not entered OCT-005; Column 3: 2 participated in CCT-006 but not entered OCT-005; Column 4: 9 participated in CCT-006 but not entered OCT-005.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "\u2264 64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "93", "spread": "9.50"}, {"groupId": "BG001", "value": "105", "spread": "8.92"}, {"groupId": "BG002", "value": "142", "spread": "8.12"}, {"groupId": "BG003", "value": "145", "spread": "8.41"}, {"groupId": "BG004", "value": "485"}]}]}, {"title": "\u2265 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "104"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "46"}, {"groupId": "BG003", "value": "44"}, {"groupId": "BG004", "value": "195"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "97"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "96"}, {"groupId": "BG003", "value": "101"}, {"groupId": "BG004", "value": "394"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Adverse Events.", "description": "Treatment-emergent adverse events (TEAE) are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.", "populationDescription": "Full Analysis Set was defined as the population of participants randomized in the core phase 2/3 SYR-322/CCT-005 (NCT01318083) or SYR-322/CCT-006 (NCT01318109) add-on studies and received at least 1 dose of the investigational products (SYR-322DB in combination with glimepiride or metformin) for the treatment period were identified for analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "52 Weeks.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "145"}]}], "classes": [{"title": "Serious Adverse Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "5"}]}]}, {"title": "Other Adverse Event (\u22653% Frequency Threshold)", "categories": [{"measurements": [{"groupId": "OG000", "value": "116"}, {"groupId": "OG001", "value": "134"}, {"groupId": "OG002", "value": "108"}, {"groupId": "OG003", "value": "113"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 8).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 8.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "141"}, {"groupId": "OG003", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.53", "spread": "0.506"}, {"groupId": "OG001", "value": "-0.65", "spread": "0.515"}, {"groupId": "OG002", "value": "-0.53", "spread": "0.486"}, {"groupId": "OG003", "value": "-0.59", "spread": "0.394"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 12).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 12.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "145"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "140"}, {"groupId": "OG003", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.63", "spread": "0.626"}, {"groupId": "OG001", "value": "-0.72", "spread": "0.589"}, {"groupId": "OG002", "value": "-0.61", "spread": "0.576"}, {"groupId": "OG003", "value": "-0.71", "spread": "0.489"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 16).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 16.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "147"}, {"groupId": "OG002", "value": "138"}, {"groupId": "OG003", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.66", "spread": "0.685"}, {"groupId": "OG001", "value": "-0.76", "spread": "0.660"}, {"groupId": "OG002", "value": "-0.69", "spread": "0.614"}, {"groupId": "OG003", "value": "-0.78", "spread": "0.495"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 20).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 20.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "136"}, {"groupId": "OG003", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.63", "spread": "0.754"}, {"groupId": "OG001", "value": "-0.70", "spread": "0.689"}, {"groupId": "OG002", "value": "-0.67", "spread": "0.648"}, {"groupId": "OG003", "value": "-0.78", "spread": "0.553"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 24).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 24.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "135"}, {"groupId": "OG003", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.59", "spread": "0.823"}, {"groupId": "OG001", "value": "-0.70", "spread": "0.740"}, {"groupId": "OG002", "value": "-0.68", "spread": "0.668"}, {"groupId": "OG003", "value": "-0.78", "spread": "0.623"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 28).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 28.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "144"}, {"groupId": "OG002", "value": "135"}, {"groupId": "OG003", "value": "132"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.62", "spread": "0.841"}, {"groupId": "OG001", "value": "-0.76", "spread": "0.721"}, {"groupId": "OG002", "value": "-0.70", "spread": "0.659"}, {"groupId": "OG003", "value": "-0.84", "spread": "0.596"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 32).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 32.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "135"}, {"groupId": "OG003", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.63", "spread": "0.868"}, {"groupId": "OG001", "value": "-0.77", "spread": "0.736"}, {"groupId": "OG002", "value": "-0.67", "spread": "0.644"}, {"groupId": "OG003", "value": "-0.81", "spread": "0.634"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 36).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 36.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "137"}, {"groupId": "OG002", "value": "134"}, {"groupId": "OG003", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.64", "spread": "0.881"}, {"groupId": "OG001", "value": "-0.77", "spread": "0.745"}, {"groupId": "OG002", "value": "-0.67", "spread": "0.659"}, {"groupId": "OG003", "value": "-0.79", "spread": "0.653"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 40).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 40.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "132"}, {"groupId": "OG003", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.66", "spread": "0.799"}, {"groupId": "OG001", "value": "-0.74", "spread": "0.779"}, {"groupId": "OG002", "value": "-0.63", "spread": "0.676"}, {"groupId": "OG003", "value": "-0.74", "spread": "0.698"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 44).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 44.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "81"}, {"groupId": "OG003", "value": "83"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.48", "spread": "0.726"}, {"groupId": "OG001", "value": "-0.71", "spread": "0.666"}, {"groupId": "OG002", "value": "-0.47", "spread": "0.787"}, {"groupId": "OG003", "value": "-0.70", "spread": "0.688"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 48).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 48.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "82"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "81"}, {"groupId": "OG003", "value": "83"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.40", "spread": "0.706"}, {"groupId": "OG001", "value": "-0.61", "spread": "0.660"}, {"groupId": "OG002", "value": "-0.36", "spread": "0.762"}, {"groupId": "OG003", "value": "-0.62", "spread": "0.707"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 52).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 52.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "89"}, {"groupId": "OG002", "value": "81"}, {"groupId": "OG003", "value": "83"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.33", "spread": "0.652"}, {"groupId": "OG001", "value": "-0.53", "spread": "0.643"}, {"groupId": "OG002", "value": "-0.29", "spread": "0.744"}, {"groupId": "OG003", "value": "-0.53", "spread": "0.790"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Final Visit).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit and glycosylated hemoglobin collected at baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Final Visit (up to 52).", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "145"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.42", "spread": "0.838"}, {"groupId": "OG001", "value": "-0.58", "spread": "0.791"}, {"groupId": "OG002", "value": "-0.44", "spread": "0.720"}, {"groupId": "OG003", "value": "-0.58", "spread": "0.781"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 8).", "description": "The change between the value of fasting blood glucose collected at week 8 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 8.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "141"}, {"groupId": "OG003", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.7", "spread": "26.50"}, {"groupId": "OG001", "value": "-19.6", "spread": "30.53"}, {"groupId": "OG002", "value": "-22.0", "spread": "22.76"}, {"groupId": "OG003", "value": "-23.4", "spread": "26.75"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 12).", "description": "The change between the value of fasting blood glucose collected at week 12 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 12.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "145"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "140"}, {"groupId": "OG003", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-22.0", "spread": "32.19"}, {"groupId": "OG001", "value": "-18.1", "spread": "29.05"}, {"groupId": "OG002", "value": "-22.9", "spread": "24.04"}, {"groupId": "OG003", "value": "-24.2", "spread": "27.30"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 16).", "description": "The change between the value of fasting blood glucose collected at week 6 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 16.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "147"}, {"groupId": "OG002", "value": "138"}, {"groupId": "OG003", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-22.3", "spread": "34.37"}, {"groupId": "OG001", "value": "-17.8", "spread": "32.22"}, {"groupId": "OG002", "value": "-21.8", "spread": "26.86"}, {"groupId": "OG003", "value": "-26.1", "spread": "26.93"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 20).", "description": "The change between the value of fasting blood glucose collected at week 20 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 20.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "136"}, {"groupId": "OG003", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-22.4", "spread": "31.75"}, {"groupId": "OG001", "value": "-22.3", "spread": "30.93"}, {"groupId": "OG002", "value": "-23.4", "spread": "27.88"}, {"groupId": "OG003", "value": "-26.1", "spread": "26.19"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 24).", "description": "The change between the value of fasting blood glucose collected at week 24 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "135"}, {"groupId": "OG003", "value": "133"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-24.0", "spread": "31.69"}, {"groupId": "OG001", "value": "-25.0", "spread": "32.68"}, {"groupId": "OG002", "value": "-25.6", "spread": "24.22"}, {"groupId": "OG003", "value": "-26.3", "spread": "28.09"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 28).", "description": "The change between the value of fasting blood glucose collected at week 28 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 28.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "144"}, {"groupId": "OG002", "value": "135"}, {"groupId": "OG003", "value": "131"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.9", "spread": "36.87"}, {"groupId": "OG001", "value": "-25.9", "spread": "33.67"}, {"groupId": "OG002", "value": "-25.8", "spread": "26.16"}, {"groupId": "OG003", "value": "-28.2", "spread": "29.49"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 32).", "description": "The change between the value of fasting blood glucose collected at week 32 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 32.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "139"}, {"groupId": "OG002", "value": "135"}, {"groupId": "OG003", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-22.4", "spread": "37.47"}, {"groupId": "OG001", "value": "-26.1", "spread": "30.69"}, {"groupId": "OG002", "value": "-23.2", "spread": "25.71"}, {"groupId": "OG003", "value": "-28.2", "spread": "29.31"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 36).", "description": "The change between the value of fasting blood glucose collected at week 36 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 36.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "134"}, {"groupId": "OG003", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-25.5", "spread": "34.16"}, {"groupId": "OG001", "value": "-26.7", "spread": "33.12"}, {"groupId": "OG002", "value": "-23.4", "spread": "24.00"}, {"groupId": "OG003", "value": "-26.0", "spread": "31.26"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 40).", "description": "The change between the value of fasting blood glucose collected at week 40 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 40.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "132"}, {"groupId": "OG003", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-21.3", "spread": "33.44"}, {"groupId": "OG001", "value": "-22.7", "spread": "30.19"}, {"groupId": "OG002", "value": "-19.8", "spread": "24.81"}, {"groupId": "OG003", "value": "-23.2", "spread": "31.13"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 44).", "description": "The change between the value of fasting blood glucose collected at week 44 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 44.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "81"}, {"groupId": "OG003", "value": "83"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.4", "spread": "31.69"}, {"groupId": "OG001", "value": "-21.9", "spread": "29.33"}, {"groupId": "OG002", "value": "-16.3", "spread": "26.22"}, {"groupId": "OG003", "value": "-24.0", "spread": "31.49"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 48).", "description": "The change between the value of fasting blood glucose collected at week 48 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 48.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "82"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "81"}, {"groupId": "OG003", "value": "83"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.6", "spread": "28.29"}, {"groupId": "OG001", "value": "-16.6", "spread": "30.68"}, {"groupId": "OG002", "value": "-14.3", "spread": "24.22"}, {"groupId": "OG003", "value": "-23.3", "spread": "29.73"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Week 52).", "description": "The change between the value of fasting blood glucose collected at week 52 and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 52.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "89"}, {"groupId": "OG002", "value": "81"}, {"groupId": "OG003", "value": "83"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.3", "spread": "31.74"}, {"groupId": "OG001", "value": "-11.9", "spread": "30.11"}, {"groupId": "OG002", "value": "-14.0", "spread": "26.92"}, {"groupId": "OG003", "value": "-16.1", "spread": "29.60"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose (Final Visit).", "description": "The change between the value of fasting blood glucose collected at final visit and baseline.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Final Visit (up to Week 52).", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "141"}, {"groupId": "OG003", "value": "145"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.0", "spread": "33.73"}, {"groupId": "OG001", "value": "-13.0", "spread": "34.68"}, {"groupId": "OG002", "value": "-16.4", "spread": "25.81"}, {"groupId": "OG003", "value": "-17.7", "spread": "29.54"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).", "description": "The change between the value of blood glucose measured by the meal tolerance test collected at week 12 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 12.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "149"}, {"groupId": "OG002", "value": "141"}, {"groupId": "OG003", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "80.2", "spread": "43.24"}, {"groupId": "OG001", "value": "80.1", "spread": "47.77"}, {"groupId": "OG002", "value": "61.6", "spread": "38.72"}, {"groupId": "OG003", "value": "64.0", "spread": "34.39"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 24).", "description": "The change between the value of blood glucose measured by the meal tolerance test collected at week 24 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "85"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87.4", "spread": "38.74"}, {"groupId": "OG001", "value": "77.9", "spread": "42.68"}, {"groupId": "OG002", "value": "60.7", "spread": "34.96"}, {"groupId": "OG003", "value": "62.4", "spread": "32.23"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 52).", "description": "The change between the value of blood glucose measured by the meal tolerance test collected at week 52 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 52.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "130"}, {"groupId": "OG003", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "83.8", "spread": "46.24"}, {"groupId": "OG001", "value": "83.2", "spread": "43.61"}, {"groupId": "OG002", "value": "62.5", "spread": "42.91"}, {"groupId": "OG003", "value": "62.7", "spread": "32.81"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).", "description": "The change between the value of blood glucose measured by the meal tolerance test collected at final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.", "populationDescription": "Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Final Visit (up to Week 52).", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}, {"id": "OG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "149"}, {"groupId": "OG002", "value": "141"}, {"groupId": "OG003", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "84.8", "spread": "45.47"}, {"groupId": "OG001", "value": "84.9", "spread": "44.35"}, {"groupId": "OG002", "value": "63.5", "spread": "43.06"}, {"groupId": "OG003", "value": "63.7", "spread": "32.32"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Treatment-emergent adverse events are any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug.", "description": "The following are included in Adverse Events tables: Column 1: 7 patients participated in CCT-005 but not entered OCT-005; Column 2: 1 participated in CCT-005 but not entered OCT-005; Column 3: 2 participated in CCT-006 but not entered OCT-005; Column 4: 9 participated in CCT-006 but not entered OCT-005.", "eventGroups": [{"id": "EG000", "title": "Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.", "seriousNumAffected": 16, "seriousNumAtRisk": 150, "otherNumAffected": 116, "otherNumAtRisk": 150}, {"id": "EG001", "title": "Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID", "description": "Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.", "seriousNumAffected": 3, "seriousNumAtRisk": 152, "otherNumAffected": 134, "otherNumAtRisk": 152}, {"id": "EG002", "title": "Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.", "seriousNumAffected": 7, "seriousNumAtRisk": 142, "otherNumAffected": 108, "otherNumAtRisk": 142}, {"id": "EG003", "title": "Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.", "seriousNumAffected": 5, "seriousNumAtRisk": 145, "otherNumAffected": 113, "otherNumAtRisk": 145}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Cerebral circulatory failure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Embolic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Enteritis infectious", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Gas gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Malignant neoplasm of renal pelvis", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Mallory-Weiss syndrome", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Pneumonia legionella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}], "otherEvents": [{"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 145}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 145}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 145}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 145}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Conjunctivitis allergic", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 145}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 145}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 145}]}, {"term": "Dental caries", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 145}]}, {"term": "Diabetic retinopathy", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 145}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 145}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 145}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 145}]}, {"term": "Hepatic steatosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 145}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 145}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Musculoskeletal stiffness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 145}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 46, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 57, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 44, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 53, "numAtRisk": 145}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Periarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 145}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 145}]}, {"term": "White blood cell count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 145}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited."}, "pointOfContact": {"title": "General Manager", "organization": "Japan Development Center, Pharmaceutical Development Division", "email": "clinicaltrialregistry@tpna.com", "phone": "+81-6-6204-5257"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "C000520853", "term": "Alogliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M247106", "name": "Alogliptin", "asFound": "Reflex", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}